Laura Palmeri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6339066/publications.pdf

Version: 2024-02-01

933447 1125743 1,720 12 10 13 citations h-index g-index papers 13 13 13 3351 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. Cancer Treatment Reviews, 2019, 73, 41-53.	7.7	69
2	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discovery, 2017, 7, 400-409.	9.4	647
3	Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. Targeted Oncology, 2017, 12, 525-533.	3.6	15
4	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 738-746.	10.7	778
5	Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study. Clinical Colorectal Cancer, 2016, 15, 213-221.	2.3	31
6	Should cirrhosis change our attitude towards treating nonâ€hepatic cancer?. Liver International, 2012, 32, 21-27.	3.9	21
7	Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer. Lung Cancer, 2010, 68, 94-98.	2.0	11
8	Weekly docetaxel in the treatment of metastatic breast cancer. Therapeutics and Clinical Risk Management, 2008, Volume 4, 1047-1059.	2.0	19
9	High efficacy of the CHOP + rituximab association in a case of primary rectal non-Hodgkin lymphoma (NHL). Leukemia and Lymphoma, 2006, 47, 1686-1687.	1.3	1
10	Regulatory Cytokine Gene Polymorphisms and Risk of Colorectal Carcinoma. Annals of the New York Academy of Sciences, 2006, 1089, 98-103.	3.8	39
11	Cytokine Gene Polymorphisms and Breast Cancer Susceptibility. Annals of the New York Academy of Sciences, 2006, 1089, 104-109.	3.8	37
12	Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site. Cancer, 2006, 107, 2898-2905.	4.1	51